cethrin
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2005 (NCT00500812)
Timeline
Indications
Studied for
Mechanism of action
- Rho-associated protein kinase 2INHIBITOR
ROCK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ba 210
- ba-210
- ba210 protein
- botulinum c3-like enzyme
- c3 exoenzyme, c. botulinum
- c3 toxin, clostridium limosum
- c3 transferase, botulinum
- cethrin
- cethrin
- cethrin
- clostridium botulinum c3 adp ribosyltransferase
- exoenzyme c3, cb
- exoenzyme c3, clostridium botulinum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02053883 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2015 | BioAxone BioSciences, Inc. |
| NCT00610337 | Phase 2 | Jan 15, 2008 | BioAxone BioSciences, Inc. |
| NCT00500812 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2005 | University of Toronto, Vertex |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioAxone BioSciences, Inc. | For profit | 2 | 2 | 2 | 2008 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Vertex | For profit | 1 | 1 | 1 | 2005 |
3 organizations
Page 1 / 1